Abstract <p>Modern biological threats, such as pandemics and zoonotic epidemics, highlight the necessity and importance of strengthening national biosecurity systems and technological sovereignty in healthcare and agriculture. At the same time, current vaccination systems face a number of serious challenges and limitations, including dependence on imported adjuvants and raw materials, logistical difficulties maintaining the cold chain, the invasiveness of traditional vaccination methods, and the generation of hazardous waste. To address these challenges, a technology is developed for producing a highly effective and safe adjuvant based on nanoscale terpene emulsions using high-pressure homogenization. Physical–chemical studies confirmed the emulsion’s high stability for 12 months at 25 ± 2°C without any signs of separation. In vitro and in vivo studies demonstrate the safety and efficacy of the resulting emulsion. The emulsion ensures effective antigen delivery and presentation and enhanced the immune response, outperforming the commercial analogue MF59 by a factor of four. The low cost and use of domestic raw materials in emulsion production will reduce the dependence on imported adjuvants and strengthen technological sovereignty, forming the basis for the development of high-tech biotechnology in the Russian Federation.</p>